Findings

What do systematic reviews say?

6 questions · 7 findings · 1 reviews · Neuromuscular

Sort:Best matchNewest Highest certainty Download CSV

No studies found 2 · 28.6%GRADE not reported 0 · 0%Very low 0 · 0%Low 5 · 71.4%Moderate 0 · 0%High 0 · 0%

BM‐MSC vs no treatment

Functional impairment · people with probable or definite amyotrophic lateral sclerosis/motor neuron disease (treated with riluzole)

2 findings from 1 review

Cell‐based therapies for amyotrophic lateral sclerosis/motor neuron disease 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 56 participants
Low
Cell‐based therapies for amyotrophic lateral sclerosis/motor neuron disease 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

BM‐MSC vs no treatment

Muscle strength · people with probable or definite amyotrophic lateral sclerosis/motor neuron disease (treated with riluzole)

The review found no eligible studies for this question.

1 finding from 1 review

Cell‐based therapies for amyotrophic lateral sclerosis/motor neuron disease 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

BM‐MSC vs no treatment

Respiratory function: change in FVC% (mean change from baseline to 12 months) · people with probable or definite amyotrophic lateral sclerosis/motor neuron disease (treated with riluzole)

1 finding from 1 review

Cell‐based therapies for amyotrophic lateral sclerosis/motor neuron disease 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 56 participants
Low

BM‐MSC vs no treatment

Overall survival · people with probable or definite amyotrophic lateral sclerosis/motor neuron disease (treated with riluzole)

BM‐MSC showed no clear difference in overall survival compared with no treatment (low certainty).

1 finding from 1 review

Cell‐based therapies for amyotrophic lateral sclerosis/motor neuron disease 2019 · Cochrane Headline outcomes only
RR 1.07 [0.94, 1.22]
1 study · 64 participants
Low

BM‐MSC vs no treatment

Adverse events, total · people with probable or definite amyotrophic lateral sclerosis/motor neuron disease (treated with riluzole)

BM‐MSC showed no clear difference in adverse events, total compared with no treatment (low certainty).

1 finding from 1 review

Cell‐based therapies for amyotrophic lateral sclerosis/motor neuron disease 2019 · Cochrane Headline outcomes only
RR 0.86 [0.62, 1.19]
1 study · 64 participants
Low

BM‐MSC vs no treatment

Serious adverse events · people with probable or definite amyotrophic lateral sclerosis/motor neuron disease (treated with riluzole)

BM‐MSC showed no clear difference in serious adverse events compared with no treatment (low certainty).

1 finding from 1 review

Cell‐based therapies for amyotrophic lateral sclerosis/motor neuron disease 2019 · Cochrane Headline outcomes only
RR 0.47 [0.13, 1.72]
1 study · 64 participants
Low